intellectual property


Why President Trump is wrong about Trans-Pacific Partnership Agreement
The TPP was generally favorable to American interests because its provisions favored American innovators, specifically biotechnology and pharmaceutical companies.
Walking the fine line between IP and public health
The rise of a protectionist US under President Donald Trump, may have long-term implications on India’s public health objectives
Will the RCEP morph into another TPP?
In highlighting that the drafts of many of its key chapters are substantially similar to those of the TPP, Sanya Reid Smith warns that the RCEP may end up as a replica of the former.
Implementation of Indo-Japan free trade agreement needs to be expedited: Nirmala Sitharaman
The pace of implementation of Indo-Japan free trade agreement needs to be further enhanced in order to exploit the huge potential of the pact, Commerce and Industry Minister Nirmala Sitharaman said.
Lessons to learn from the demise of the TPP
With the imminent demise of the Tran-Pacific Partnership Agreement almost certain, there are many lessons to be learnt from the fraudulent free trade deal.
Investigation: As Colombia pushes for cancer drug price-cut and considers compulsory licensing, Novartis responds with quiet filing of an investment treaty notice
Novartis lodged a formal notice of dispute under the Switzerland-Colombia BIT.
Trade deals can have adverse impact on access to generic medicines
Interview with Dr Peter Ghys, interim director, strategic information and evaluation, UNAIDS
Report shows trade agreements have boosted medicine and copyright monopolies
Global pharmaceutical companies have successfully lobbied for longer monopolies in trade agreements which have delayed the availability of cheaper medicines, resulting in higher prices.
Don’t cry over dead trade agreements
If we can manage our own economies well, new trade pacts will become largely redundant.
The Regional Comprehensive Economic Partnership, intellectual property protection and access to medicines
This paper identifies TRIPS-Plus provisions in leaked RCEP negotiating texts and examines their implications for low and middle-income countries.